Presentation (forthcoming): MedInvest Oncology Conference (December 7-10, 2021)
Propella Therapeutics, Inc. will be presenting at the MedInvest Oncology Conference on December 7, 2021, at 10:40-11:00 a.m. (ET).
Presentation: Abstract 337037: A Phase 1/2a, Open-label, Multicenter Study of Intramuscular Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)
/in presentations /by georgePropella Therapeutics, Inc. presented “A Phase 1/2a, Open-label, Multicenter Study of Intramuscular Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)” at the American Society of Clinical Oncology Annual Meeting on June 4, 2021.
Presentation: Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model (citation and abstract are found at https://meetinglibrary.asco.org/record/194919/abstract)
/in presentations /by georgePropella Therapeutics, Inc. presented “Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model” at the American Society of Clinical Oncology Genitourinary Cancers Symposium on February 11, 2021.
Presentation: Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target
/in presentations /by georgePropella Therapeutics, Inc. presented a webinar titled “Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target” on February 9, 2021.
Presentation: A Phase 2 Double-Blind Clinical Trial (VZU00025) to Examine the Tolerability, Safety and Effects of CGS-200-0 (Vehicle), CGS-200-1 (1% Capsaicin Topical Liquid) and CGS-200-5 (5% Capsaicin Topical Liquid) on Osteoarthritis Knee Pain (OAKP) (Presented at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020)
/in presentations /by georgePropella Therapeutics, Inc. presented the results of its recently completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020.
Presentation: A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
/in presentations /by neilView the results of our Phase 2 clinical study of CGS-200-5 presented at the 2019 ACR Annual Meeting View Abstract
